DUODOPA now publicly available for Nova Scotian’s with Parkinson’s Disease

AbbVie, a global research and development-based biopharmaceutical company, announces that Canadians diagnosed with advanced Parkinson’s Disease living in Nova Scotia now have public access to DUODOPA.

Parkinson’s disease (PD) is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. The symptoms generally come on slowly over time. Early in the disease, the most obvious are shaking, rigidity, slowness of movement, and difficulty with walking. Currently, there is no cure.

“We hear from people with Parkinson’s and their families every day,” says Ryan Underhill, Managing Director for Parkinson Canada in Nova Scotia. “Having public access to effective treatment options gives them a sense of hope.  We see firsthand how very challenging this disease is for individuals managing their unique symptoms through all stages of disease progression.”

DUODOPA is used to treat patients with advanced Parkinson’s disease who have severe and disabling motor symptoms that cannot be well controlled with available oral treatments. It is a levodopa and carbidopa medication combination delivered in the form of a gel through an intestinal pump.

“We are thrilled that Nova Scotians now have access to DUODOPA,” says Stéphane Lassignardie, General Manager of AbbVie Canada. “We continue to work with the healthcare community and the government to bring our medications to different communities. Our mission is to continue to advance scientific innovation in therapeutic areas where there are limited or no treatment options available to patients.”

Over 25 people are diagnosed with Parkinson’s every day in Canada1. Between 2011 – 2031, the number of Canadians diagnosed with Parkinson’s is expected to double to more than 163,7002.


Neurological Health Charities Canada (NHCC), Health Canada, Public Health Agency of Canada (PHAC), Canadian Institute of Health Research (CIHR). MAPPING CONNECTIONS: An Understanding of Neurological Conditions in Canada. Sept. 2014. pg.66.

POHEM-Neurological, Statistics Canada and Public Health Agency of Canada. Table 3-5: Projected prevalence, by select neurological condition, Canada, 2011, 2016, 2021, 2026, and 2031, Microsimulation Project. Ibid.,

Be the first to comment

Leave a Reply

Your email address will not be published.